主要論文・著書 | - Ishibashi T, Inagaki K, Okazawa M, Yamagishi A, Ohta-Ogo K, Asano R, Masaki T, Kotani Y, Ding X, Chikaishi-Kirino T, Maedera N, Shirai M, Hatakeyama K, Kubota Y, Kishimoto T, Nakaoka Y. IL-6/gp130 signaling in CD4+ T cells drives the pathogenesis of pulmonary hypertension. Proc Natl Acad Sci U S A. 2024 Apr 16;121(16):e2315123121. doi: 10.1073/pnas.2315123121. Epub 2024 Apr 11.
- Manabe Y, Ishibashi T, Asano R, Tonomura S, Maeda Y, Motooka D, Ueda J, Yanagawa M, Edamoto-Taira Y, Chikaishi-Kirino T, Masaki T, Inagaki T, Nakamura S, Katada Y, Okazawa M, Narazaki M, Ogo T, Kumanogoh A, Nakaoka Y*. Gut Dysbiosis is associated with aortic aneurysm formation and progression in Takayasu arteritis. Arthritis Res Ther. 2023 March 24; 25(1); 46. doi:1186/s13075-023-03031-9.
- Yaku A, Inagaki T, Asano R, Okazawa M, Mori H, Sato A, Hia F, Masaki T, Manabe Y, Ishibashi T, Vandenbon A, Nakatsuka Y, Akaki K, Yoshinaga M, Uehata T, Mino T, Ishibashi-Ueda H, Morinobu A, Tsujimura T, Ogo T, Nakaoka Y*, Takeuchi O*. Regnase-1 prevents pulmonary arterial hypertension via mRNA degradation of Interleukin-6 and Platelet-Derived Growth Factor in alveolar macrophages. Circulation. 2022 Sep 27;146(13):1006-1022 (*equal contribution, *co-correspondence)
- Harigai M, Miyamae T, Hashimoto H, Yoshida A, Yamashita K, Nakaoka Y. A Multicentre, Large-Scale, Observational Study of Tocilizumab in Patients with Takayasu Arteritis in Japan: The ACT-Bridge Study. Mod Rheumatol. 2022 Sep 3; roac099. doi:10.1093/mr/roac099. Online ahead of print.
- Nakaoka Y*, Yanagawa M, Hata A, Yamashita K, Okada N, Yamakido S, Hayashi H, Jayne D. Vascular imaging of patients with refractory Takayasu arteritis treated with tocilizumab: post hoc analysis of a randomized controlled trial. Rheumatology (Oxford). 2022 May 30; 61(6):2360-2368. doi: 10.1093/rheumatology/keab684.
- Masaki T, Okazawa M, Asano R, Inagaki T, Ishibashi T, Yamagishi A, Mizushima S, Nishimura M, Manabe Y, Ishibashi-Ueda H, Shirai M, Tsuchimochi H, Pearson JT, Kumanogoh A, Sakata Y, Ogo T, Kishimoto T, Nakaoka Y*. Aryl hydrocarbon receptor is essential for the pathogenesis of pulmonary arterial hypertension. Proc Natl Acad Sci U S A. 118(11): e2023899118, 2021
- Inagaki T, Pearson JT, Tsuchimochi H, Schwenke DO, Saito S, Higuchi T, Masaki T, Umetani K, Shirai M, Nakaoka Y. * Evaluation of right coronary vascular dysfunction in severe pulmonary hypertensive rats using synchrotron radiation microangiography. Am J Physiol Heart Circ Physiol. 2021 Mar 1; 320(3):H1021-H1036. doi:10.1152/ajpheart.00327.2020. Epub 2021 Jan 22.
- Arita Y, Nakaoka Y, Eda Y, Kitabayashi K, Hasegawa S. Perioperative Management of Takayasu Arteritis for Cardiac Surgery in a Patient Treated With Tocilizumab. J Am Coll Cardiol Case Rep. 2020 Oct 7; 2(15); 2363–2367.doi: 10.1016/j.jaccas.2020.07.039. eCollection 2020 Dec.
- Nakaoka Y*, Yamashita K, Yamakido S. Comment on: Long-term efficacy and safety of tocilizumab in refractory Takayasu arteritis: final results of the randomized controlled phase 3 TAKT study: reply. Rheumatology (Oxford). 2020 Sep 1;59(9):e48-e49. doi: 10.1093/rheumatology/keaa255.
- Mori H, Ishibashi T, Inagaki T, Okazawa M, Masaki T, Asano R, Manabe Y, Ohta-Ogo K, Narazaki M, Ishibashi-Ueda H, Kumanogoh A,Nakaoka Y*. Pristane/Hypoxia (PriHx) Mouse as a Novel Model of Pulmonary Hypertension Reflecting Inflammation and Fibrosis. Circ J. 2020 Jun 25;84(7):1163-1172.
- Minato T, Nirasawa S, Sato T, Yamaguchi T, Hoshizaki M, Inagaki T, Nakahara K, Yoshihashi T, Ozawa R, Yokota S, Natsui M, Koyota S, Yoshiya T, Yoshizawa-Kumagaye K, Motoyama S, Gotoh T, Nakaoka Y, Penninger JM, Watanabe H, Imai Y, Takahashi S, Kuba K. B38-CAP is a bacteria-derived ACE2-like enzyme that suppresses hypertension and cardiac dysfunction. Nat Commun. 2020 Feb 26;11(1):1058. doi: 10.1038/s41467-020-14867-z
- Isobe M, Amano K, Arimura Y, Ishizu A, Ito S, Kaname S, Kobayashi S, Komagata Y, Komuro I, Komori K, Takahashi K, Tanemoto K, Hasegawa H, Harigai M, Fujimoto S, Miyazaki T, Miyata T, Yamada H, Yoshida A, Wada T, Inoue Y, Uchida HA, Ota H, Okazaki T, Onimaru M, Kawakami T, Kinouchi R, Kurata A, Kosuge H, Sada KE, Shigematsu K, Suematsu E, Sueyoshi E, Sugihara T, Sugiyama H, Takeno M, Tamura N, Tsutsumino M, Dobashi H, Nakaoka Y, Nagasaka K, Maejima Y, Yoshifuji H, Watanabe Y, Ozaki S, Kimura T, Shigematsu H, Yamauchi-Takihara K, Murohara T, Momomura SI; JCS Joint Working Group. JCS 2017 Guideline on Management of Vasculitis Syndrome - Digest Version. Circ J. 2020 Jan 24;84(2):299-359. doi: 10.1253/circj.CJ-19-0773.
- Nakaoka Y, Isobe M, Tanaka Y, Ishii T, Ooka S, Niiro H, Tamura N, Banno S, Yoshifuji H, Sakata Y, Kawakami A, Atsumi T, Furuta S, Kohsaka H, Suzuki K, Hara R, Maejima Y, Tsukamoto H, Takasaki Y, Yamashita K, Okada N, Yamakido S, Takei S, Yokota S, and Nishimoto N. Long-term efficacy and safety of tocilizumab in refractory Takayasu arteritis: final results of the randomised controlled phase 3 TAKT study. Rheumatology (Oxford). 2020 Jan 17. pii: kez630. doi: 10.1093/rheumatology/kez630. [Epub ahead of print]PMID:31951279
- Terao C, Yoshifuji H, Matsumura T, Naruse TK, Ishii T, Nakaoka Y, Kirino Y, Matsuo K, Origuchi T, Shimizu M, Maejima Y, Amiya E, Tamura N, Kawaguchi T, Takahashi M, Setoh K, Ohmura K, Watanabe R, Horita T, Atsumi T, Matsukura M, Miyata T, Kochi Y, Suda T, Tanemoto K, Meguro A, Okada Y, Ogimoto A, Yamamoto M, Takahashi H, Nakayamada S, Saito K, Kuwana M, Mizuki N, Tabara Y, Ueda A, Komuro I, Kimura A, Isobe M, Mimori T, Matsuda F. Genetic determinants and an epistasis of LILRA3 and HLA-B*52 in Takayasu arteritis. Proc Natl Acad Sci U S A. 2018 Dec 18;115(51):13045-13050.
- Kim KH, Nakaoka Y, Augustin HG, Koh GY. Myocardial Angiopoietin-1 Controls Atrial Chamber Morphogenesis by Spatiotemporal Degradation of Cardiac Jelly. Cell Reports, 23, 2455-2466, May 22, 2018
- Nakaoka Y*, Isobe M, Takei S, Tanaka Y, Ishii T, Yokota S, Nomura A, Yoshida S, Nishimoto N. Efficacy and safety of tocilizumab in patients with refractory Takayasu arteritis: results from a randomized, double-blind, placebo-controlled, phase 3 trial in Japan (the TAKT study). Ann Rheum Dis. 2018 Mar; 77(3):348-354. doi: 10.1136/annrheumdis-2017-211878. Epub 2017 Nov 30.
- Yasui T, Masaki T, Arita Y, Ishibashi T, Inagaki T, Okazawa M, Oka T, Shioyama W, Yamauchi-Takihara K, Komuro I, Sakata Y, Nakaoka Y*. Molecular Characterization of Striated Muscle-specific Gab1 Isoform as a Critical Signal Transducer for Neuregulin-1/ErbB Signaling in Cardiomyocytes. PLoS One. 2016 Nov 18;11(11): e0166710. doi: 10.1371/journal.pone.0166710
- Han S, Lee SJ, Kim KE, Lee HS, Oh N, Park I, Ko E, Oh SJ, Lee YS, Kim D, Lee S, Lee DH, Lee KH, Chae SY, Lee JH, Kim SJ, Kim HC, Kim S, Kim SH, Kim C, Nakaoka Y, He Y, Augustin HG, Hu J, Song PH, Kim YI, Kim P, Kim I, Koh GY. Amelioration of sepsis by TIE2 activation-induced vascular protection. Sci Transl Med. 2016 Apr 20;8(335):335ra55. doi: 10.1126/scitranslmed.aad9260.9.
- Furuta K, Yoshida Y, Ogura S, Kurahashi T, Kizu T, Maeda S, Egawa M, Chatani N, Nishida K, Nakaoka Y, Kiso S, Kamada Y, Takehara T. Gab1 adaptor protein acts as a gatekeeper to balance hepatocyte death and proliferation during acetaminophen-induced liver injury in mice. Hepatology. 2016 Apr;63(4):1340-55. doi: 10.1002/hep.28410. Epub 2016 Jan 22.
- Hashimoto-Kataoka T, Hosen N, Sonobe T, Arita Y, Yasui T, Masaki T, Minami M, Inagaki T, Miyagawa S, Sawa Y, Murakami M, Kumanogoh A, Yamauchi-Takihara K, Okumura M, Kishimoto T, Komuro I, Shirai M, Sakata Y, Nakaoka Y.* Interleukin-6/interleukin-21-signaling axis is critical in the pathogenesis of pulmonary arterial hypertension. Proc Natl Acad Sci U S A. 2015 May 19; 112(20): E2677-86.
- Arita Y, Nakaoka Y*, Matsunaga T, Kidoya H, Yamamizu K, Arima Y, Hashimoto-Kataoka T, Ikeoka K, Yasui T, Masaki T, Yamamoto K, Higuchi K, Park JS, Shirai M, Nishiyama K, Yamagishi H, Otsu K, Kurihara H, Minami T, Yamauchi-Takihara K, Koh GY, Mochizuki N, Takakura N, Sakata Y, Yamashita JK, Komuro I. Myocardium-derived angiopoietin-1 is essential for coronary vein formation in the developing heart. Nat Commun. 2014 Jul 29; 5: 4552. doi: 10.1038/ncomms5552.
- Lee J, Kim KE, Choi DK, Jang JY, Jung JJ, Kiyonari H, Shioi G, Chang W, Suda T, Mochizuki N, Nakaoka Y, Komuro I, Yoo OJ, Koh GY. Angiopoietin-1 guides directional angiogenesis through integrin αvβ5 signaling for recovery of ischemic retinopathy. Sci Transl Med. 2013 Sep 18;5(203):203ra127. doi: 10.1126/scitranslmed.3006666.
- Nakaoka Y*, Higuchi K, Arita Y, Otsuki M, Yamamoto K, Hashimoto-Kataoka T, Yasui T, Ikeoka K, Ohtani T, Sakata Y, Shima Y, Kumanogoh A, Yamauchi-Takihara K, Tanaka T, Kishimoto T, Komuro I. Tocilizumab for the Treatment of the Patients with Refractory Takayasu Arteritis. Int Heart J. 54, 406-411, 2013
- Shioyama W, Nakaoka Y*, Higuchi K, Minami T, Nishida K, Taniyama Y, Kidoya H, Arita Y, Hashimoto T, Fujio Y, Shirai M, Takakura N, Morishita R, Yamauchi-Takihara K, Kodama T, Hirano T, Mochizuki N, Komuro I*. Gab1 is essential for postnatal angiogenesis via hepatocyte growth factor/c-Met signaling. Circ Res. 108, 664-675, 2011.
- Koyama T¶, Nakaoka Y¶*, Fujio Y, Hirota H, Nishida K, Sugiyama S, Okamoto K, Yamauchi-Takihara K, Yoshimura M, Mochizuki S, Hori M, Hirano T, Mochizuki N. Interaction of Scaffolding Adaptor Protein Gab1 with Tyrosine Phosphatase SHP2 Negatively Regulates IGF-I-dependent Myogenic Differentiation via the ERK1/2 Signaling Pathway. J Biol Chem. 283: 24234-24244, 2008
- Nakaoka Y*, Nishida K, Narimatsu M, Kamiya A, Minami T, Sawa H, Okawa K, Fujio Y, Koyama T, Maeda M, Sone M, Yamasaki S, Arai Y, Koh GY, Kodama T, Hirota H, Otsu K, Hirano T, and Mochizuki N*. Gab family proteins are essential for postnatal maintenance of cardiac function through transmitting neuregulin-1/ErbB signaling. J Clin Invest. 117: 1771-1781, 2007
- Nakaoka Y, Nishida K, Fujio Y, Izumi M, Terai T, Oshima Y, Sugiyama S, Matsuda S, Koyasu S, Yamauchi-Takihara K, Hirano T, Kawase I, Hirota H. Activation of gp130 Transduces Hypertrophic Signal Through Interaction of Scaffolding Docking Protein Gab1 With Tyrosine Phosphatase SHP2 in Cardiomyocytes. Circ Res. 93: 221-229, 2003
(*corresponding author) |
---|